KING STEVEN W 4
4 · Oncotelic Therapeutics, Inc. · Filed Jul 16, 2021
Insider Transaction Report
Form 4
KING STEVEN W
Director
Transactions
- Conversion
Common Stock
2021-03-31+3,291,720→ 3,330,647 total(indirect: By Artius Bioconsulting) - Award
Stock Options
2021-07-08+357,412→ 357,412 totalExercise: $0.16From: 2021-07-08Exp: 2031-07-08→ Common Stock (357,412 underlying) - Conversion
Series A Convertible Preferred Stock
2021-03-31−3,292→ 0 total(indirect: By Artius Bioconsulting)→ Common Stock (3,291,720 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
- [F2]Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant.
- [F3]Shares of the Series A Convertible Preferred Stock does not expire.